Cat No. 37-N29

Ponatinib

10mg

For research purposes only

Ponatinib, also known as AP24534, is considered to be a pan-BCR-ABL inhibitor. It was specifically designed to bind BCR-ABL with very high potency and to inhibit the entire spectrum of mutants conferring resistance against other tyrosine kinase inhibitors (TKIs), such as VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosporylation and LYN among others, including the T315I mutant that is resistant to all current therapies. It has been shown to suppress BCR-ALB(T315I)-driven tumor growth in mice.

TECHNICAL INFORMATION



Other Names: 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl) methyl]-3-(trifluoromethyl)phenyl]-benzamide

Chemical Formula: $C_{29}H_{27}F_3N_6O$

CAS Number: 943319-70-8

PubChem Substance ID: 24826799

Molecular Weight: 532.56

Purity: >98%

Appearance: Pale Yellow solid

Solubility: DMSO

IC_{50} : 0.5 & 11 nM

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO.

REFERENCES

1. Zirm. E., et al. (2012). Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. BR J Haematol. 157:483-92.
2. Lierman. E., et al. (2012). Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 26:1693-5.
3. Gozgit, J.M., et al (2012). Ponatinib (AP24534), a multitargeted pan-FGFR-amplified or mutated cancer models. Mol Cancer Ther. 11:690-9.